Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers.
CBP
PD-L1
colon cancer
metastatic liver cancer
β-catenin
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
30 Apr 2019
30 Apr 2019
Historique:
received:
22
11
2018
accepted:
14
04
2019
entrez:
21
5
2019
pubmed:
21
5
2019
medline:
21
5
2019
Statut:
epublish
Résumé
Immune checkpoint blockade with specific antibodies can accelerate anti-tumor immunity, resulting in clinical responses in patients with various types of cancer. However, these antibodies achieve only partial tumor regression. Thus, a wide variety of treatment combinations based on programmed death-ligand 1 (PD-L1) pathway inhibition are under development to enhance such therapeutic effects. In this study, the effects of combination treatment using PRI-724, a selective inhibitor of CBP/β-catenin, and an anti-PD-L1 antibody were examined in a mouse model of colon cancer liver metastasis. Mice were inoculated with SL4 colon cancer cells to produce metastatic liver tumors. The combination treatment resulted in regression of tumor growth, whereas monotherapy with each treatment individually failed to exhibit any anti-tumor activity. In addition, co-administration of the inhibitor and antibody induced CD8
Identifiants
pubmed: 31105882
doi: 10.18632/oncotarget.26892
pii: 26892
pmc: PMC6508964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3013-3026Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST There is no conflicts of interest.
Références
Hepatology. 2004 Nov;40(5):1180-9
pubmed: 15486931
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Nat Med. 2008 Feb;14(2):162-9
pubmed: 18246080
Nat Rev Immunol. 2008 Aug;8(8):581-93
pubmed: 18617885
Annu Rev Immunol. 2009;27:591-619
pubmed: 19132916
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cancer Res. 2011 Sep 1;71(17):5670-7
pubmed: 21846824
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
J Immunol. 2012 Sep 1;189(5):2110-7
pubmed: 22815287
J Clin Invest. 2013 Feb;123(2):834-43
pubmed: 23298833
Hepatology. 2014 Jul;60(1):224-36
pubmed: 24700550
J Clin Invest. 2014 Jun;124(6):2599-610
pubmed: 24837430
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Clin Invest. 2015 Mar 2;125(3):1269-85
pubmed: 25689248
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Oncotarget. 2015 Sep 15;6(27):23720-34
pubmed: 26125441
Cancer Res. 2016 Feb 1;76(3):513-6
pubmed: 26772756
EBioMedicine. 2015 Oct 08;2(11):1751-8
pubmed: 26870800
Cancer Sci. 2017 May;108(5):853-858
pubmed: 28267224
Sci Rep. 2017 Mar 23;7(1):325
pubmed: 28336942